Cambridge Healthtech Institute’s 3rd Annual

Neoantigen Targeted Therapies

Personalized Cancer Immunotherapy in the Genomic Era

August 30-31, 2018

Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target previously undruggable space. Developments in NGS technology enabled systematic analysis of patient-specific mutanome and opens the door to developing personalized cancer vaccines and other therapies targeting neoantigens. Cambridge Healthtech Institute’s Third Annual Neoantigen Targeted Therapies meeting brings together thought leaders from pharmaceutical and biotech companies, leading academic teams and clinical immuno-oncologists to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer, including utilizing NGS to identify tumor-specific neoantigens, using in silico tools to predict immunogenic neoepitopes, and targeting them with personalized vaccines, novel antibodies or combination therapies.

Preliminary Agenda


Vaccibody’s Approach to Cost-Effective Personalized Cancer Neoantigen Vaccines Inducing a Unique CD8-Dominated T Cell Response

Agnete Fredriksen, PhD, CSO, Vaccibody

Agenus’ Synthetic Neoantigen Vaccine Platforms, Including Novel Phosphopeptide Tumor Targets

Daniel Levey, PhD, Senior Director Vaccine Research, R&D, Agenus, Inc.

Harnessing the Innate Immunogenicity of Foreign Viral Antigens to Fight Solid Tumors

David Anderson, PhD, CSO, Research & Development, VBI Vaccines, Inc.

Cross-Talk among Distinct Immune Regulatory and Effector Cells in Cancer in Different Tissues

Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute

A New Source of Highly Immunogenic Neoepitopes for Cancer Vaccines

Stephen Albert Johnston, PhD, Director, Center for Innovations in Medicine; Professor, School of Life Sciences, Biodesign Institute, Arizona State University; CEO, Calviri, Inc.


Design and Development of a Therapeutic Antibody Targeting a Novel Neoantigen

Philip Arlen, MD, President & CEO, Precision Biologics

T Cells against Tumor Neoantigens: How Many Are Likely Needed for Clinical Efficacy and Can Contemporary Vaccines Get Us There?

Andrew Allen, PhD, CEO & President, Gritstone Oncology


Developing Cancer Vaccines in the Era of Checkpoint Blockade: Avoiding the T Cell Trap

Yared Hailemichael, PhD, Research Instructor, Melanoma Medical Oncology, The UT MD Anderson Cancer Center

Th1 Epitopes for Versatile Tumor- and Patient-Tailored Vaccine Combination Therapies (VCT)

William C. Watt, PhD, President & CEO, EpiThany

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286